We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt
Osmind
Mental Health Care
San Francisco, CA 10,596 followers
The premier technology platform for breakthrough mental health treatment and research.
About us
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-generating medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org. We're hiring! Learn more at osmind.org/careers
- Website
-
http://osmind.org/
External link for Osmind
- Industry
- Mental Health Care
- Company size
- 51-200 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
San Francisco, CA, US
Employees at Osmind
Updates
-
“Dr. Will Goes to Washington" - Live Debrief of the FDA’s Decision on PTSD Treatments this Thursday 🏛️ Our CMO, William Sauvé, MD presented at the FDA Advisory Committee meeting on PTSD treatment. Get the inside story in our next community event. Join us Thursday, July 31st at 11am PDT / 2 pm ET for an exclusive debrief in the Psychiatry Collective. Dr. Sauvé will share: 🔍 What really happens inside FDA advisory meetings 💊 The committee's vote and what it means for PTSD treatment 🎖️ Why veteran mental health remains a regulatory challenge 💬 Your questions about the regulatory process Join for a candid conversation about a pivotal moment in PTSD care. Space is limited to Psychiatry Collective members. RSVP below in the comments👇:
-
-
We're hiring; come transform mental health care! Open Roles: •Director of RCM: https://lnkd.in/dVHqC9CD •Implementation Specialist: https://lnkd.in/dXQEnF54 •RCM Prior Auth / Benefits Verification Specialist: https://lnkd.in/dNkt7y4M •Lead Product Manager https://lnkd.in/dJMR4Xcw
-
Thinking about accepting insurance at your psychiatry practice? It can seem overwhelming, but with the right roadmap, it's absolutely manageable. Most practices expect a 2-month timeline. Smart practices plan for 4-6 months. You're working with payer approval processes and committee meetings on schedules you can't control. When you understand the dependency chain—contract approval, then credentialing, then EDI enrollment—you can plan accordingly. If you're offering TMS or Spravato, there are additional steps, but they're predictable once you know what to expect. Just like in medicine, an ounce of prevention is worth a pound of cure. The key is having a clear timeline, proper documentation, and the right billing partner who understands psychiatry's unique requirements. Our complete guide walks you through each step so you can expand your practice with confidence: https://lnkd.in/dCShZQaz
-
Happening Wednesday, July 23rd, 9AM - 9:30 AM PDT: Join us for an informal coffee chat hosted by Osmind CMO, William Sauvé, MD and Don Vaughn, Ph.D., CEO of Ampa, for a live Q&A. No slides, no lectures—just real talk with fellow clinicians and a cup of coffee! ☕ This is your chance to ask anything about Ampa—from device functionality to implementation in your practice. We'll have a topic to kick things off, but it's an open mic—jump in with your own questions or ideas about the Ampa device. Bring questions or topics or just listen in! Links to RSVP in comments 👇
-
-
Happening now: (link to watch: https://lnkd.in/dq7itwgY)
The FDA has invited our Chief Medical Officer, William Sauvé, MD, to present at this Friday's Psychopharmacologic Drugs Advisory Committee. The Committee will review the supplemental new drug application submitted by Otsuka for brexpiprazole tablets, in combination with sertraline, as a potential treatment for adults with PTSD. The FDA convenes advisory committees for critical public health matters—PTSD affects 5-6% of Americans annually, with higher rates among veterans. Dr. Sauve's expertise spans military psychiatry, inpatient PTSD programs, and clinical innovation at Osmind. He will address treatment gaps and advocate for higher standards of care, bringing decades of frontline experience to regulatory discussions that shape treatment advancement. The meeting streams live and archives for later viewing—essential viewing for anyone developing PTSD treatments or seeking better patient outcomes. Watch here: https://lnkd.in/dq7itwgY
-
-
The FDA has invited our Chief Medical Officer, William Sauvé, MD, to present at this Friday's Psychopharmacologic Drugs Advisory Committee. The Committee will review the supplemental new drug application submitted by Otsuka for brexpiprazole tablets, in combination with sertraline, as a potential treatment for adults with PTSD. The FDA convenes advisory committees for critical public health matters—PTSD affects 5-6% of Americans annually, with higher rates among veterans. Dr. Sauve's expertise spans military psychiatry, inpatient PTSD programs, and clinical innovation at Osmind. He will address treatment gaps and advocate for higher standards of care, bringing decades of frontline experience to regulatory discussions that shape treatment advancement. The meeting streams live and archives for later viewing—essential viewing for anyone developing PTSD treatments or seeking better patient outcomes. Watch here: https://lnkd.in/dq7itwgY
-
-
Happening Thursday, Jul 17 at 11:00 AM - 11:30 AM PDT: Join two TMS pioneers, Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS and William Sauvé, MD, for our live Psychiatry Collective event. Discuss all things psychiatry with fellow forward-thinking clinicians: 🔹 Practical Guidance on Running & Growing Your Practice: Get expert strategies on financial sustainability, workflow optimization, staff management, and insurance navigation. 🔹 Insights on Interventional Psychiatry: Stay up to date on Spravato, TMS, psychedelics, neuromodulation, and the latest advancements in psychiatric care. 🔹 A Collaborative, Informal Discussion: No slides or lectures—just candid conversations and peer-driven learning in a supportive environment. Bring questions or topics or just listen in! Links to RSVP in comments 👇
-
-
🚨 Every Spravato practice needs this. The FDA requires specific consent procedures for Spravato treatments. Get it wrong = regulatory violations, liability risks, and claim denials. We've created a comprehensive consent form that covers: ✅ Complete FDA/REMS compliance with all required safety information ✅ Legal protection through professionally drafted language covering risks, alternatives, and patient responsibilities ✅ Insurance optimization with proper documentation to support prior authorizations and reduce claim denials ✅ Patient-friendly format that improves understanding and treatment compliance Skip the hours of research and drafting. Download our proven template 📋 https://lnkd.in/dRAZ_s-y
-
Here's what you're missing this month in the Osmind Psychiatry Collective: •Psychedelics for treating substance abuse: Brittany Albright MD, MPH shared research on psychedelics showing 66% of participants reduced alcohol consumption and 49% decreased tobacco use after psychedelic experiences. The study also found 48-72% reported better impulse control. "This study opens the door to future research examining psychedelics and their effects on wellness, not simply psychopathology," she noted. •Metabolic Psychiatry: Bret Scher, MD, sparked discussion by sharing Christopher Palmer, MD's perspective: "Mental health disorders are metabolic disorders of the brain." Members dove into the strong connections between metabolic and mental health, with clinicians sharing success stories from implementing ketogenic therapy as adjuvant treatment. •The age of AI: William Sauvé, MD sparked a discussion on AI vs. physician diagnostics. Some members expressed concerns about AI replacing human empathy in therapy, while others questioned whether we're training doctors to win at computer games rather than practice actual medicine. The conversation touched on everything from neuropsychological testing to whether patients actually prefer AI therapists. 80 new members joined just in the last month, sharing real-world insights you don't find in journals alone. Join the discussion, including weekly live virtual events. (links in comments below 👇)
-